-
1
-
-
77951755278
-
Pancreatic cancer
-
Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
-
(2010)
N Engl J Med
, vol.362
, pp. 1605-1617
-
-
Hidalgo, M.1
-
2
-
-
34248141223
-
Tumor-stroma interactions in pancreatic ductal adenocarcinoma
-
DOI 10.1158/1535-7163.MCT-06-0686
-
Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97. (Pubitemid 46711982)
-
(2007)
Molecular Cancer Therapeutics
, vol.6
, Issue.4
, pp. 1186-1197
-
-
Mahadevan, D.1
Von Hoff, D.D.2
-
3
-
-
19944409357
-
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial
-
DOI 10.1016/S1470-2045(05)70175-3, PII S1470204505701753
-
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005;6:369-76. (Pubitemid 40753742)
-
(2005)
Lancet Oncology
, vol.6
, Issue.6
, pp. 369-376
-
-
Reni, M.1
Cordio, S.2
Milandri, C.3
Passoni, P.4
Bonetto, E.5
Oliani, C.6
Luppi, G.7
Nicoletti, R.8
Galli, L.9
Bordonaro, R.10
Passardi, A.11
Zerbi, A.12
Balzano, G.13
Aldrighetti, L.14
Staudacher, C.15
Villa, E.16
Di, C.V.17
-
4
-
-
50249087586
-
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: Is an anti-VEGF strategy still applicable?
-
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26:463-71.
-
(2008)
Invest New Drugs
, vol.26
, pp. 463-471
-
-
Ko, A.H.1
Dito, E.2
Schillinger, B.3
Venook, A.P.4
Xu, Z.5
Bergsland, E.K.6
-
5
-
-
77955887676
-
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303)
-
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3617-3622
-
-
Kindler, H.L.1
Niedzwiecki, D.2
Hollis, D.3
Sutherland, S.4
Schrag, D.5
Hurwitz, H.6
-
6
-
-
0037100983
-
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
-
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161-7.
-
(2002)
Br J Cancer
, vol.87
, pp. 161-167
-
-
Bramhall, S.R.1
Schulz, J.2
Nemunaitis, J.3
Brown, P.D.4
Baillet, M.5
Buckels, J.A.6
-
7
-
-
79958119999
-
Anti-angiogenic agents in pancreatic cancer: A review
-
Assifi MM, Hines OJ. Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 2011;11:464-9.
-
(2011)
Anticancer Agents Med Chem
, vol.11
, pp. 464-469
-
-
Assifi, M.M.1
Hines, O.J.2
-
9
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
10
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Vinals, F.6
-
11
-
-
84863704553
-
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
-
Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2:270-87.
-
(2012)
Cancer Discov
, vol.2
, pp. 270-287
-
-
Sennino, B.1
Ishiguro-Oonuma, T.2
Wei, Y.3
Naylor, R.M.4
Williamson, C.W.5
Bhagwandin, V.6
-
12
-
-
79961011555
-
The heparanase system and tumor metastasis: Is heparanase the seed and soil?
-
Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 2011;30:253-68.
-
(2011)
Cancer Metastasis Rev
, vol.30
, pp. 253-268
-
-
Arvatz, G.1
Shafat, I.2
Levy-Adam, F.3
Ilan, N.4
Vlodavsky, I.5
-
13
-
-
77956624954
-
Proteoglycans in health and disease: New concepts for heparanase function in tumor progression and metastasis
-
Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010;277:3890-903.
-
(2010)
FEBS J
, vol.277
, pp. 3890-3903
-
-
Barash, U.1
Cohen-Kaplan, V.2
Dowek, I.3
Sanderson, R.D.4
Ilan, N.5
Vlodavsky, I.6
-
14
-
-
0036637267
-
Roles of heparan-sulphate glycosaminoglycans in cancer
-
Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8. (Pubitemid 37328933)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.7
, pp. 521-528
-
-
Sasisekharan, R.1
Shriver, Z.2
Venkataraman, G.3
Narayanasami, U.4
-
15
-
-
1342343091
-
Involvement of stromal proteoglycans in tumour progression
-
DOI 10.1016/j.critrevonc.2003.10.005
-
Wegrowski Y, Maquart FX. Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 2004;49:259-68. (Pubitemid 38251357)
-
(2004)
Critical Reviews in Oncology/Hematology
, vol.49
, Issue.3
, pp. 259-268
-
-
Wegrowski, Y.1
Maquart, F.-X.2
-
16
-
-
79952728727
-
Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity
-
Ramani VC, Yang Y, Ren Y, Nan L, Sanderson RD. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 2011;286:6490-9.
-
(2011)
J Biol Chem
, vol.286
, pp. 6490-6499
-
-
Ramani, V.C.1
Yang, Y.2
Ren, Y.3
Nan, L.4
Sanderson, R.D.5
-
17
-
-
79955528442
-
Extracellular matrix and cell signalling: The dynamic cooperation of integrin, proteoglycan and growth factor receptor
-
Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 2011;209:139-51.
-
(2011)
J Endocrinol
, vol.209
, pp. 139-151
-
-
Kim, S.H.1
Turnbull, J.2
Guimond, S.3
-
18
-
-
31544436071
-
Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival
-
DOI 10.1002/cncr.21648
-
Quiros RM, Rao G, Plate J, Harris JE, Brunn GJ, Platt JL, et al. Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 2006;106:532-40. (Pubitemid 43157615)
-
(2006)
Cancer
, vol.106
, Issue.3
, pp. 532-540
-
-
Quiros, R.M.1
Rao, G.2
Plate, J.3
Harris, J.E.4
Brunn, G.J.5
Platt, J.L.6
Gattuso, P.7
Prinz, R.A.8
Xu, X.9
-
19
-
-
0035875082
-
Heparanase expression in primary and metastatic pancreatic cancer
-
Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 2001;61:4655-9. (Pubitemid 32691870)
-
(2001)
Cancer Research
, vol.61
, Issue.12
, pp. 4655-4659
-
-
Koliopanos, A.1
Friess, H.2
Kleeff, J.3
Shi, X.4
Liao, Q.5
Pecker, I.6
Vlodavsky, I.7
Zimmermann, A.8
Buchler, M.W.9
-
20
-
-
52549127242
-
High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF
-
discussion 1681-2
-
Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, et al. High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 2008;12:1674-81; discussion 1681-2.
-
(2008)
J Gastrointest Surg
, vol.12
, pp. 1674-1681
-
-
Hoffmann, A.C.1
Mori, R.2
Vallbohmer, D.3
Brabender, J.4
Drebber, U.5
Baldus, S.E.6
-
21
-
-
0037156954
-
Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma
-
Rohloff J, Zinke J, Schoppmeyer K, Tannapfel A, Witzigmann H, Mossner J, et al. Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma. Br J Cancer 2002;86:1270-5.
-
(2002)
Br J Cancer
, vol.86
, pp. 1270-1275
-
-
Rohloff, J.1
Zinke, J.2
Schoppmeyer, K.3
Tannapfel, A.4
Witzigmann, H.5
Mossner, J.6
-
23
-
-
34247637147
-
Heparanase: A target for drug discovery in cancer and inflammation
-
DOI 10.1038/sj.bjp.0707182, PII 0707182
-
McKenzie EA. Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 2007;151:1-14. (Pubitemid 46675998)
-
(2007)
British Journal of Pharmacology
, vol.151
, Issue.1
, pp. 1-14
-
-
McKenzie, E.A.1
-
24
-
-
84860271832
-
Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis
-
Ferro V, Liu L, Johnstone KD, Wimmer N, Karoli T, Handley P, et al. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem 2012;55:3804-13.
-
(2012)
J Med Chem
, vol.55
, pp. 3804-3813
-
-
Ferro, V.1
Liu, L.2
Johnstone, K.D.3
Wimmer, N.4
Karoli, T.5
Handley, P.6
-
25
-
-
79951676056
-
PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
-
Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 2011;104:635-42.
-
(2011)
Br J Cancer
, vol.104
, pp. 635-642
-
-
Dredge, K.1
Hammond, E.2
Handley, P.3
Gonda, T.J.4
Smith, M.T.5
Vincent, C.6
-
26
-
-
0032874771
-
An orthotopic in vivo model of human pancreatic cancer
-
DOI 10.1016/S0039-6060(99)70099-1
-
Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. An orthotopic in vivo model of human pancreatic cancer. Surgery 1999;126:562-7. (Pubitemid 29421045)
-
(1999)
Surgery
, vol.126
, Issue.3
, pp. 562-567
-
-
Schwarz, R.E.1
McCarty, T.M.2
Peralta, E.A.3
Diamond, D.J.4
Ellenhorn, J.D.I.5
-
27
-
-
0346455774
-
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
-
DOI 10.1101/gad.1158703
-
Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26. (Pubitemid 38040774)
-
(2003)
Genes and Development
, vol.17
, Issue.24
, pp. 3112-3126
-
-
Aguirre, A.J.1
Bardeesy, N.2
Sinha, M.3
Lopez, L.4
Tuveson, D.A.5
Horner, J.6
Redston, M.S.7
DePinho, R.A.8
-
28
-
-
77950806356
-
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer
-
Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010;70:2852-61.
-
(2010)
Cancer Res
, vol.70
, pp. 2852-2861
-
-
Dineen, S.P.1
Roland, C.L.2
Greer, R.3
Carbon, J.G.4
Toombs, J.E.5
Gupta, P.6
-
29
-
-
84863127628
-
Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation
-
Arnold SA, Rivera LB, Carbon JG, Toombs JE, Chang CL, Bradshaw AD, et al. Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation. PLoS One 2012;7:e31384.
-
(2012)
PLoS One
, vol.7
-
-
Arnold, S.A.1
Rivera, L.B.2
Carbon, J.G.3
Toombs, J.E.4
Chang, C.L.5
Bradshaw, A.D.6
-
30
-
-
36148954658
-
On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing
-
DOI 10.1007/s10555-007-9087-6, Forty Years of Metastasis Research: A Tribute to Dr. Isaiah J. Fidler
-
Man S, Munoz R, Kerbel RS. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 2007;26:737-47. (Pubitemid 350115117)
-
(2007)
Cancer and Metastasis Reviews
, vol.26
, Issue.3-4
, pp. 737-747
-
-
Man, S.1
Munoz, R.2
Kerbel, R.S.3
-
31
-
-
0037162555
-
Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis
-
DOI 10.1073/pnas.152070599
-
Goldshmidt O, Zcharia E, Abramovitch R, Metzger S, Aingorn H, Friedmann Y, et al. Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A 2002;99:10031-6. (Pubitemid 34831167)
-
(2002)
Proceedings of the National Academy of Sciences of the United States of America
, vol.99
, Issue.15
, pp. 10031-10036
-
-
Goldshmidt, O.1
Zcharia, E.2
Abramovitch, R.3
Metzger, S.4
Aingorn, H.5
Friedmann, Y.6
Schirrmacher, V.7
Mitrani, E.8
Vlodavsky, I.9
-
33
-
-
80052453669
-
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype
-
Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 2011;17:5822-32.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5822-5832
-
-
Carbone, C.1
Moccia, T.2
Zhu, C.3
Paradiso, G.4
Budillon, A.5
Chiao, P.J.6
-
34
-
-
79959421475
-
HIF-1alpha mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression
-
Yoo YG, Christensen J, Gu J, Huang LE. HIF-1alpha mediates tumor hypoxia to confer a perpetual mesenchymal phenotype for malignant progression. Sci Signal 2011;4:pt4.
-
(2011)
Sci Signal
, vol.4
, Issue.PART 4
-
-
Yoo, Y.G.1
Christensen, J.2
Gu, J.3
Huang, L.E.4
-
35
-
-
79951820679
-
HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function
-
Yoo YG, Christensen J, Huang LE. HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 2011;71:1244-52.
-
(2011)
Cancer Res
, vol.71
, pp. 1244-1252
-
-
Yoo, Y.G.1
Christensen, J.2
Huang, L.E.3
-
36
-
-
34547610957
-
uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells
-
DOI 10.1083/jcb.200701092
-
Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007;178:425-36. (Pubitemid 47196151)
-
(2007)
Journal of Cell Biology
, vol.178
, Issue.3
, pp. 425-436
-
-
Lester, R.D.1
Jo, M.2
Montel, V.3
Takimoto, S.4
Gonias, S.L.5
-
37
-
-
67651146533
-
Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
-
Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009;8:1761-71.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 1761-1771
-
-
Roland, C.L.1
Dineen, S.P.2
Lynn, K.D.3
Sullivan, L.A.4
Dellinger, M.T.5
Sadegh, L.6
-
38
-
-
47949097072
-
Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
-
Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, et al. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008;68:4340-6.
-
(2008)
Cancer Res
, vol.68
, pp. 4340-4346
-
-
Dineen, S.P.1
Lynn, K.D.2
Holloway, S.E.3
Miller, A.F.4
Sullivan, J.P.5
Shames, D.S.6
-
39
-
-
79955509614
-
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice
-
Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, et al. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 2011;121:1709-21.
-
(2011)
J Clin Invest
, vol.121
, pp. 1709-1721
-
-
Lerner, I.1
Hermano, E.2
Zcharia, E.3
Rodkin, D.4
Bulvik, R.5
Doviner, V.6
-
40
-
-
34547820876
-
+ myeloid cells
-
DOI 10.1038/nbt1323, PII NBT1323
-
Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20. (Pubitemid 47236916)
-
(2007)
Nature Biotechnology
, vol.25
, Issue.8
, pp. 911-920
-
-
Shojaei, F.1
Wu, X.2
Malik, A.K.3
Zhong, C.4
Baldwin, M.E.5
Schanz, S.6
Fuh, G.7
Gerber, H.-P.8
Ferrara, N.9
-
41
-
-
34047274961
-
In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas: Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation
-
DOI 10.1074/jbc.M604218200
-
Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, et al. in vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 2007;282:2363-73. (Pubitemid 47076771)
-
(2007)
Journal of Biological Chemistry
, vol.282
, Issue.4
, pp. 2363-2373
-
-
Xu, X.1
Rao, G.2
Quiros, R.M.3
Kim, A.W.4
Miao, H.-Q.5
Brunn, G.J.6
Platt, J.L.7
Gattuso, P.8
Prinz, R.A.9
-
42
-
-
79953293124
-
Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma
-
Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T, et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 2011;71:2772-80.
-
(2011)
Cancer Res
, vol.71
, pp. 2772-2780
-
-
Meirovitz, A.1
Hermano, E.2
Lerner, I.3
Zcharia, E.4
Pisano, C.5
Peretz, T.6
-
43
-
-
79959266354
-
M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis
-
Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 2011;6:e21106.
-
(2011)
PLoS One
, vol.6
-
-
Zhou, H.1
Roy, S.2
Cochran, E.3
Zouaoui, R.4
Chu, C.L.5
Duffner, J.6
-
44
-
-
83355169753
-
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial
-
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:4548-54.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4548-4554
-
-
Von Hoff, D.D.1
Ramanathan, R.K.2
Borad, M.J.3
Laheru, D.A.4
Smith, L.S.5
Wood, T.E.6
-
45
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
46
-
-
77952239575
-
The PG500 series: Novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
-
Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 2010;28:276-83.
-
(2010)
Invest New Drugs
, vol.28
, pp. 276-283
-
-
Dredge, K.1
Hammond, E.2
Davis, K.3
Li, C.P.4
Liu, L.5
Johnstone, K.6
-
47
-
-
33749008541
-
Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis
-
DOI 10.1158/0008-5472.CAN-06-1382
-
Zhao H, Liu H, Chen Y, Xin X, Li J, Hou Y, et al. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis. Cancer Res 2006;66:8779-87. (Pubitemid 44449195)
-
(2006)
Cancer Research
, vol.66
, Issue.17
, pp. 8779-8787
-
-
Zhao, H.1
Liu, H.2
Chen, Y.3
Xin, X.4
Li, J.5
Hou, Y.6
Zhang, Z.7
Zhang, X.8
Xie, C.9
Geng, M.10
Ding, J.11
-
48
-
-
80052357047
-
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer
-
Song K, Li Q, Jiang ZZ, Guo CW, Li P. Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer. Cancer Biol Ther 2011;12:388-98.
-
(2011)
Cancer Biol Ther
, vol.12
, pp. 388-398
-
-
Song, K.1
Li, Q.2
Jiang, Z.Z.3
Guo, C.W.4
Li, P.5
-
49
-
-
80051690789
-
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
-
Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5299-5310
-
-
Allen, E.1
Walters, I.B.2
Hanahan, D.3
-
50
-
-
20444394457
-
A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer
-
DOI 10.1038/sj.onc.1208602
-
Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 2005;24:4037-51. (Pubitemid 40897051)
-
(2005)
Oncogene
, vol.24
, Issue.25
, pp. 4037-4051
-
-
Joyce, J.A.1
Freeman, C.2
Meyer-Morse, N.3
Parish, C.R.4
Hanahan, D.5
|